Aribio’s Four Hyaluronic Acid Fillers Receive Product Approval in Indonesia
Four Types of "Bidan" Approved
Discussions Underway with Local Aesthetic Companies for Supply and Product Launch
Aribio and AribioLab announced on September 8, 2026, that four types of their self-developed hyaluronic acid (HA) filler brand "Bidan" have received product approval from Indonesia’s National Food and Drug Agency (BPOM).
"Bidan" is an HA filler that Aribio Group spent seven years developing for the anti-aging and medical aesthetics market. The product applies Aribio’s proprietary "PCRT" technology, which enhances the uniformity and viscoelasticity of HA particles, and incorporates the "HCCL" process to reduce residual crosslinkers.
According to Aribio, the product’s biocompatibility, efficacy, and safety were verified through human application tests led by Professor Heo Changhoon’s team from the Department of Dermatology at Seoul National University Bundang Hospital. Based on these results, Aribio obtained marketing approval in Korea.
With a population of approximately 300 million, Indonesia is the world’s fourth most populous country, and its medical aesthetics market continues to expand alongside economic growth.
Hot Picks Today
"Even on the Way to Work, There Are Lines at the 'Yellow Sign'... Mega MGC Coffee Achieves KRW 400 Million Sales Per Store with KRW 1,500 Coffee"
- "70 Billion Spent, But Just a 'Luxury Greenhouse'? ... A Disappointing First Weekend at the Yeosu Islands Expo"
- "Wow!" Ten Minutes of Human Cheer Becomes Doomsday for Birds... '1,700 Dead, Air Devastated'
- "The Smart Newcomer Never Stops Working... This 'Rookie' Is Intimidating [Click e-Industry]"
- "My Husband Went to the Han River Every Night"... Private Investigator Reveals Hidden Stories Behind Running Clubs
Aribio Group is currently in discussions with local aesthetics companies regarding supply and product launches, following the BPOM product approval. The group plans to secure local distribution networks and accelerate its entry into the Indonesian market.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
